Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry

Clinical Biochemistry

Volumn 43, Issue 12, 2010, Pages 992-997

  Li, Nai jing ^a   Liu, Wen tao ^b   Li, Wei ^b   Li, Sheng qi ^a   Chen, Xiao hui ^b   Bi, Kai shun ^b   He, Ping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Liquid chromatography; Mass spectrometry; Metabonomics; Plasma

Indexed keywords

BIOLOGICAL MARKER; SPHINGOSINE; TRYPTOPHAN;

AGED; ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLOMICS; NEUROLOGIC DISEASE; PLASMA; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; BLOOD; MIDDLE AGED;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED;

EID: 77954315742     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.04.072     Document Type: Article

References (31)

1. Kaddurah-Daouk R., Bruce S.K., Richard M.W. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008, 48:653-683.
2. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics and its role in drug development and disease diagnosis. Expert Rev. Mol. Diagn. 2004, 4:189-199.
3. Wishart D.S. Applications of metabolomics in drug discovery and development. Drugs R&D 2008, 9:307-322.
4. Yin P., Mohemaiti P., Chen J., Zhao X., Lu X., Yimit A., et al. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry. J. Chromatogr.B 2008, 871:322-327.
5. Jia L., Wang C., Kong H., Yang J., Li F., Xu G. Effect of PA-MSHA vaccine on plasma phospholipids metabolic profiling and the ratio of Th2/Th1 cells within immune organ of mouse IgA nephropathy. J Pharm Biomed Anal 2007, 43:646-654.
6. Jia L., Wang C., Kong H., Cai Z., Xu G. Plasma phospholipid metabolic profiling and biomarkers of mouse IgA nephropathy. Metabolomics 2006, 2:95-104.
7. Inagaki S., Noda T., Min J.Z., Toyo'oka T. Metabolic profiling of rat hair and screening biomarkers using ultra performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry. J Chromatogr A 2007, 1176:94-99.
8. Jia L., Chen J., Yin P., Lu X., Xu G. Serum metabonomics study of chronic renal failure by ultra performance liquid chromatography coupled with Q-TOF mass spectrometry. Metabolomics 2008, 4:183-189.
9. Murdoch T.B., Fu H., MacFarlane S., Sydora B.C., Fedorak R.N., Slupsky C.M. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal Chem 2008, 80:5524-5531.
10. Scalbert A., Milenkovic D., Llorach R., Manach C., Leroux C. Energy and protein metabolism and nutrition, issue 124 2007, 259-276. Wageningen Academic Publishers, Netherlands.
11. Gibney M.J., Walsh M., Brennan L., Roche H.M., German B., van Ommen B. Metabolomics in human nutrition: opportunities and challenges. Am J Clin Nutr 2005, 82:497-503.
12. Yin P., Zhao X., Li Q., Wang J., Li J., Wang G. Metabonomics study of intestinal fistulas based on ultraperformance liquid chromatography coupled with Q-TOF mass spectrometry (UPLC/Q-TOF MS). J Proteome Res 2006, 5:2135-2143.
13. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004, 1:213-225.
14. Yin P., Mohemaiti P., Chen J., Zhao X., Lu X., Yimiti Adilijiang, Upur Halmurat, Xu G. Serum metabolic profiling of abnormal savda by liquid chromatography/mass spectrometry. J Chromatogr. B 2008, 871:322-327.
15. Huo T., Cai S., Lu X., Sha Y., Yu M., Li F. Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J Pharm Biomed Anal 2009, 49:976-982.
16. Farooqui A.A., Horrocks L.A., Farooqui T. Deacylation and reacylation of neural membrane glycerophospholipids. J Mol Neurosci 2000, 14:123-135.
17. Ross B.M., Moszczynska A., Erlich J., Kish S.J. Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem 1998, 70:786-793.
18. Behl Christian Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol 1999, 57:301-323.
19. Zhu X., Raina A.K., Lee H., et al. Oxidative stress signalling in Alzheimer's disease. Brain Res 2004, 1000:32-39.
20. XU Y., Xiao Y.J., Zhu K., Baudhuin L.M., Lu J., Hong G., Kim K.S. Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets 2003, 3:23-32.
21. Han X.M., Holtzman D., McKeel D.W., Kelley J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 2002, 82:809-818.
22. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J. Clin. Invest. 2002, 110:3-8.
23. Yang F., Yan S.K., Wang F., He Y., Guo Y.J., Zhou Q., et al. DNA immunization perturbs lipid metabolites and increases risk of atherogenesis. J Proteome Res 2008, 7:741-748.
24. Bourbon N.A., Sandirasegarane L., Kester M. Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. J Biol Chem 2002, 277:3286-3292.
25. Hu W., Xu R., Zhang G., Jin J., Szulc Z.M., Bielawski J., et al. Golgi fragmentation is associated with the ceramide-induced cellular effects. Mol Biol Cell 2005, 16:1555-1567.
26. Hannun Y.A., Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol 2000, 10:73-80.
27. Kolesnick R., Hannun Y.A. Ceramide and apoptosis. Trends Biochem Sci 1999, 24:224-225.
28. Panganamala R.V., Jack C., David Geer, Cornwell G. Long-chain bases in the sphingolipids of atherosclerotic human aorta. J Lipid Res 1969, 10:445-455.
29. Wolf H. Studies on tryptophan metabolism in man. Scandinavian J. Clin. Lab. Invest. 1974, 136:1-186.
30. Baran H., Jellinger K., Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999, 106:165-181.
31. Widner B., Leblhuber F., Walli J., Tilz G.P., Demel U., Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 2000, 107:343-353.